Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093911 | 0.88 | LMNA (0.66) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL15264404 | 0.86 | SMN1; SMN2 (0.50) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3043717 | 0.85 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL29954749 | 0.82 | ADRB2 (0.51) | LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3041875 | 0.81 | LMNA (0.49) | LMNASMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL10104444 | 0.78 | ALDH1A1 (0.69) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL1592029 | 0.77 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL1592096 | 0.77 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL1592027 | 0.77 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL15094178 | 0.77 | ALDH1A1 (0.61) | LMNASMN1; SMN2ALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2828253-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| CN-101679309-B | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2012-02-29 | — | — | CN | disclosed |
| CN-101679309-A | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| US-7659271-B2 | Pyrimidine compound having dibenzylamine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-2149563-A1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | Kowa Company. Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | KOWA COMPANY, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | CETP, NPC1L1, MTTP | LMNA 2286/4885SMN1; SMN2 4868/4885ALDH1A1 4452/4885 |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | CPS1, FABP4, VHL | LMNA 3782/4885SMN1; SMN2 1925/4885ALDH1A1 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.